Merck & Co. has submitted a new drug application for omarigliptin, its investigational once-weekly DPP-4 inhibitor for the treatment of Type 2 diabetes, to the Japanese Pharmaceuticals and Medical Devices Agency. Japan is the first country with a regulatory filing for omarigliptin.

Worldwide, Merck is supporting omarigliptin with a clinical development program that includes nine Phase III clinical trials involving approximately 7,500 patients with Type 2 diabetes in support of planned regulatory filings.

Source: Merck & Co.